spacer
home > pmps > autumn 2013 > auto-injector innovation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Auto-Injector Innovation

Driven by the efficacy and immunogenic natures of large molecule biological medicines, the growth of biologics and biosimilars has been evident in recent years – and continues to play a major role in the pipelines of biopharma companies and their acquisition strategies.

As the need for injectable delivery solutions for use with these large molecule biologics increases, the trend
for self-administration devices is showing significant growth. Indeed, the demand for devices such as auto-injectors and pen injectors has not only increased, but is evolving. There is now a need for device designs to be even more innovative, while also adhering to applicable quality and compliance guidelines and, most importantly, patient needs.

As a result, it is paramount for combination product manufacturers to have a thorough understanding of established regulations – as well as to introduce technological and industrial device design innovations – to maintain market competitiveness through higher patient acceptance and compliance.

FDA Combination Product Definitions

The US Food and Drug Administration (FDA) defines a ‘combination product’ as a medical product that consists of two or more components with any combination of drug/device, biologics/device, drug/ biologic, drug/device/biologic, and so on, that together makes a single combined medical product through design, packaging or labelling.

There are four main product categories: single entity combination; co-packaged combination; cross-labelled combination; and cross-labelled combination with an approved product.

Auto-injectors and pen injectors are considered to be single entity combination products, as they comprise two or more regulated components (for example, drug/device or biologic/ device) that are physically, chemically, or otherwise combined or mixed, and produced as single entities.

Manufacturing Partnerships


Although the method of collaboration for every auto-injector or pen injector project may differ, it is common for biopharma companies to work with a primary container partner to provide the prefilled syringe or cartridge inside the device, and with a secondary packaging partner to design and manufacture the device constituent.

Each of these constituent parts is subject to their corresponding current Good Manufacturing Practice (cGMP) regulations before and after they are combined. It is vital that the biopharma companies, which market and distribute the final combination product, make certain that their chosen partners are also well-informed about the latest compliance guidelines and consider them at all stages of development.

However, in addition to regulatory compliance, the ultimate goal for biopharma companies is to market a product that enhances patient compliance through innovative device designs that provide dose accuracy, enhance usability and improve overall safety. This is where the right device manufacturer partner can play a critical role: by not only comprehending and integrating into the device design the injection requirements inputted by the biopharma company (taking into account possible issues the primary container may have when the constituents combine), but also innovating within the sphere of applicable quality and compliance.

The Final Rule

Over the past few years, manufacturers of auto-injectors and pen injectors have had to rely on the FDA’s 2009 Draft Guidance for Industry and FDA: Current Good Manufacturing Practice for Combination Products for regulatory insights and guidelines. Fortunately, as of 22nd January 2013, the FDA streamlined the cGMP for combination products and issued the Final Rule for 21 CFR Part 4 – Current Good Manufacturing Practice Requirements for Combination Products – effective as of 22nd July 2013.

While the Final Rule does not create new requirements per se, it does help clarify and solidify the FDA’s position on how to appropriately apply the two regulatory systems – cGMP and quality system regulation (QSR) – to combination products.

Taking single-entity combination products as an example, the FDA now clearly states that the corresponding drug and/or device constituents retain their corresponding regulatory status both before and after they are combined. For device manufacturers that already have QSR in place, some additional supplements, such as stability testing and expiration dating, would have to be supplemented where applicable.

In-House Capabilities

For the biopharma company planning to launch a drug or biologic in a combination device like an auto-injector or pen injector, choosing a device partner that already has a proven and streamlined quality system that is continuously improved is crucial, especially if the company has limited device knowledge and related experience.

The ideal device partner would not only be able to demonstrate that its quality system complies to the latest regulations, but also that its design teams are well aware of how that system affects their designs at every point of the development stage. To achieve this in the most effective way, the chosen device manufacturer partner should have, at the very least, an in-house team of mechanical and industrial to familiarise themselves with device usage before any actual injection is taken. This method can help reduce patient anxiety and prevent improper use that can lead to a fear of taking future injections.

Other supporting tools, such as instructions for use, videos and even specialised labels, can further help with patient compliance and enhance confidence when using these devices. For example, customised labels with special materials that offer anti-slip features may help with grip when a user exerts too much downward force during injection.

Quality and Innovation

A device manufacturer that houses key manufacturing capabilities such as tooling, moulding and assembly allows the designers to more efficiently and accurately verify and translate their designs into production. Although it is safe to assume that most designers always aim for manufacturability, the results during actual development testing may differ. If the key teams are not working together for the same company, this can cause delays due to miscommunication with regards to design translations.

It is more ideal to have design teams working closely with the manufacturing teams (such as tooling) under one roof, to ensure that functionalities specified by the DIR can be quickly verified when development testing. With all device-related manufacturing in-house, design engineers will also have the advantage of verifying and validating their novel designs with critical activities such as tolerance analysis, assembly processes, material selection, and single-cavity to multi-cavity transitions.

Stimulated Market

The recent introduction of numerous biologics and biosimilars, and their corresponding advanced delivery specifications, has quickly created a new segment in the drug delivery technologies market in recent years. This sector, which is often recognised as the combination product device technologies market, has stimulated the need to update and combine various existing regulatory guidelines, understand new patient usage needs and advance innovative device designs.

Furthermore, biopharma companies now have to work even closer with device manufacturing partners to ensure the final device/drug combination products are not only compliant and meet patient needs, but are also innovative enough to be competitive in the market.

The ideal device manufacturing partner should have a solid quality system implemented at all development stages, and a strong team of designers and engineers that understand and follow the associated design controls while innovating devices that address HFE and patient compliance. Even more importantly, a partner with a full suite of critical manufacturing capabilities in-house allows for the designer’s innovations to be realised in a verified production form.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Steven Kaufman is responsible for the global marketing and public relations strategy at the SHL Group, a leading designer, developer and manufacturer of advanced drug delivery devices. Steven has extensive experience in Chinese and Western management cultures, having worked for 15 years in Taiwan and five years in North America. He has a BA from the University of Western Ontario, and completed his MBA coursework in Marketing and International Business at National Chengchi University, Taiwan.
spacer
Steven Kaufman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers

Finding the Right End-to-End Safety Solution for Your Needs

Bioclinica

With upcoming changes, including the implementation of the International Conference on Harmonisation (ICH) E2B(R3) Electronic Transmission of Individual Case Safety Report and Identification of Medicinal Products (IDMP) standards, the current state of safety reporting can be confusing. Your existing safety system may not be flexible enough to accommodate these changing regulations, which are still moving targets regarding the details needed for a comprehensive solution with the right level of processes, company-to-company integrations and finalized regional rules.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement